<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
- --------------------------------------------------------------------------------
Sangstact Medical Corporation
- --------------------------------------------------------------------------------
Name of Issuer
Common Stock
- --------------------------------------------------------------------------------
Title of Class of Securities
801003104
- --------------------------------------------------------------------------------
CUSIP Number
May 21, 1998
- --------------------------------------------------------------------------------
Date of event which requires filing of this statement
Check the appropriate box to designate the rule pursuant to which this schedule
is filed:
[x] Rule 13d - 1(b)
[ ] Rule 13d - 1(c)
[ ] Rule 13d - 1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
CUSIP No: 801003104
1. Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
UBS Asset Management (New York) Inc.
Tax ID: 13-2725861
2. Check the Appropriate Box if a Member of a Group
a.[ ]
b.[ ]
3. SEC Use Only
4. Citizenship or Place of Organization
New York
5. Sole Voting Power:
60,000
Number of 6. Shared Voting Power:
Shares -0-
Beneficially
Owned by 7. Sole Dispositive Power:
Each 835,000
Reporting
Person 8. Shared Dispositive Power:
With -0-
9. Aggregate Amount Beneficially Owned by Each Reporting Person
835,000
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
11. Percent of Class Represented by Amount in Row (9)
5.21%
12. Type of Reporting Person
IA
2
<PAGE> 3
CUSIP Number: 801003104
1. Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
UBS (Lux) Equity Invest-Biotech, a Subfund of UBS (Lux) Equity Invest
c/o INTRAG International Equity Invest (Company for Fund Management) S.A.
2. Check the Appropriate Box if a Member of a Group
a.[ ]
b.[ ]
3. SEC Use Only
4. Citizenship or Place of Organization
Luxembourg
5. Sole Voting Power:
775,000
Number of
Shares 6. Shared Voting Power:
Beneficially -0-
Owned by
Each 7. Sole Dispositive Power:
Reporting -0-
Person
With 8. Shared Dispositive Power:
-0-
9. Aggregate Amount Beneficially Owned by Each Reporting Person
775,000
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
11. Percent of Class Represented by Amount in Row (9)
4.84%
12. Type of Reporting Person
00
3
<PAGE> 4
Item 1(a) Name of Issuer: Sangstat Medical Corporation (the "Company")
(b) Address of Issuer's Principal Executive Offices:
1505 Adams Drive
Menlo Park, CA 94025
Item 2(a) - (c). Name, Principal Business Address, and Citizenship of Persons
Filing:
UBS Asset Management (New York) Inc.
1345 Avenue of the Americas
New York, New York 10105
UBS (Lux) Equity Invest-Biotech, a subfund of UBS (Lux) Equity Invest
c/o INTRAG International Equity Invest (Company for Fund Management)
S.A., 3-5, Place Winston Churchill, B.P. 134 2011 Luxembourg
(d) Title of Class of Securities: Common Stock
(e) CUSIP Number: 801003104
Item 3. This statement is filed pursuant to Rule 13d-1(b).
UBS Asset Management (New York) Inc. is an investment adviser
registered under Section 203 of the Investment advisers Act of 1940.
Item 4. Ownership.
UBS Asset Management (New York) Inc. is an investment adviser registered
under U.S. law. UBS (Lux) Equity Invest-Biotech, a subfund of UBS (Lux)
Equity Inc. is an investment fund organized under Luxembourg law. UBS Asset
Management (New York) Inc. beneficially owns 835,000 shares of the Company's
Common Stock (representing approximately 5.21% of the outstanding shares of such
Common Stock). UBS Asset Management (New York) Inc. possesses the power to
dispose of and direct the disposition of 835,000 shares and possesses the power
to vote 60,000 shares. UBS (Lux) Equity Invest-Biotech, a Subfund of UBS (Lux)
Equity Invest benefically owns 775,000 shares of the company's common stock
representing 4.84% of the outstanding shares and such common stock. UBS (Lux)
Equity Invest-Biotech, a Subfund of UBS (Lux) Equity Invest possesses the power
to vote or direct the vote of 775,000 Shares. The holdings listed above are as
of May 21, 1998.
4
<PAGE> 5
Item 5. Ownership of Five Percent or Less of a Class.
Not Applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
See Item 4.
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported by the Parent Holding Company.
Not Applicable.
Item 8. Identification and Classification of Members of the Group.
Not Applicable.
Item 9. Notice of Dissolution of the Group.
Not Applicable.
Item 10. By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the ordinary course of
business and were not acquired for the purpose and do not have the effect of
changing or influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any transaction having
such purpose or effect.
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
UBS Asset Management (New York) Inc.
Joe Scavo June 1, 1998
- ------------------------------- ---------------------
Title: Director of Compliance Date
INTRAG International Equity Trust (Company for Fund Management) S.A.
Gilbert Schintgen June 1, 1998
- -------------------------------- ---------------------
Title: Director Date
Manuel Hauser June 1, 1998
- -------------------------------- ---------------------
Title: Director Date
5
